https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
310d) and OS (255d vs. not reached). Sensitivity for MP to identify clinical progression was 54% and specificity was 100%. MP calls were from samples taken a median of 28d into treatment and 39d before FFUI. Patients with MMR (n=27) had significantly longer PFS and OS compared to those with neither call (n=51). These results demonstrated that ctDNA changes early after treatment initiation inform response to treatment and correlate with long-term clinical outcomes. Once validated, molecular response assessment can enable ear
Like
Comment
Share
